Midcap pharma, a robust story: Gajendra Nagpal

If you could just highlights your thoughts on Glenmark Pharma and most of the other pharmaceutical companies within the midcap arena which have been doing fairly for themselves?

Gajendra Nagpal: As I was putting the argument forward in a market like this you would see lot of midcap stocks they would assert themselves because when there is a feeling that the broader markets or the stocks which are index based are reasonably priced or little richly priced and the sentiment continues to remain buoyant there is a natural tendency for the smart money to flow into the midcap space.

As far as the midcap pharmaceutical stocks are concerned, the story there continues to remain very robust though the valuations are still again one can keep discussing on it whether something is there in the short run or not because in a market where the people are very hungry for some information to be coming, some tie up some of the midcap pharmaceutical companies have been able to get their act together very very strongly and I do believe that they are going to outperform the market but in the short run whether they will be able to seriously outperform the markets I do not know because as I was pointing out the valuation are reasonable but by and large from the medium term to long term standpoint the midcap pharmaceutical stocks have to be the forming part of the core portfolio of any investor.